Patents by Inventor Michael DECI

Michael DECI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods to block and bind CXCR4 to modulate cellular function
    Patent number: 12435148
    Abstract: Provided are composition comprising antibodies directed to the N-terminal domain of CXCR4. The antibody may be a scFv and can be fused to a RNA binding peptide. The fusion protein can be complexed to RNAi, such as micro RNA. The complexes can be used for targeting delivery of RNAi molecules to CXCR4 expressing cancer cells, as well as inhibiting the binding of CXCR4 to CXCL12.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: October 7, 2025
    Assignee: The Research Foundation for The State University of New York
    Inventors: Juliane Nguyen, Michael Deci
  • Compositions and methods to block and bind CCR2 to modulate cellular function
    Patent number: 12428485
    Abstract: Provided herein are single chain variable fragment antibodies that are directed against N-terminal or extracellular loop regions of CCR2. The scFvs can be used alone or in combination to modify macrophage number and migration and to reduce the growth of tumors.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: September 30, 2025
    Assignee: The Research Foundation for The State University of New York
    Inventors: Juliane Nguyen, Michael Deci
  • COMPOSITIONS AND METHODS TO BLOCK AND BIND CXCR4 TO MODULATE CELLULAR FUNCTION
    Publication number: 20220281986
    Abstract: Provided are composition comprising antibodies directed to the N-terminal domain of CXCR4. The antibody may be a scFv and can be fused to a RNA binding peptide. The fusion protein can be complexed to RNAi, such as micro RNA. The complexes can be used for targeting delivery of RNAi molecules to CXCR4 expressing cancer cells, as well as inhibiting the binding of CXCR4 to CXCL12.
    Type: Application
    Filed: July 13, 2020
    Publication date: September 8, 2022
    Inventors: Juliane NGUYEN, Michael DECI
  • COMPOSITIONS AND METHODS TO BLOCK AND BIND CCR2 TO MODULATE CELLULAR FUNCTION
    Publication number: 20220220212
    Abstract: Provided herein are single chain variable fragment antibodies that are directed against N-terminal or extracellular loop regions of CCR2. The scFvs can be used alone or in combination to modify macrophage number and migration and to reduce the growth of tumors.
    Type: Application
    Filed: May 13, 2020
    Publication date: July 14, 2022
    Inventors: Juliane NGUYEN, Michael DECI